Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 5/20 | 0.61 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.61 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | PTGES | O14684 | 1/20 | 0.61 |
| ▸ | XPO1 | O14980 | 1/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RARB | P10826 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8951207 | 0.99 | PLA2G4A (0.61) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL9586166 | 0.93 | CYSLTR2 (0.60) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL8423166 | 0.91 | PLA2G4A (0.59) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL8153771 | 0.91 | PLA2G4A (0.59) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL8166125 | 0.91 | PLA2G4A (0.59) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL8161239 | 0.91 | PLA2G4A (0.59) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL6357802 | 0.91 | CYSLTR1 (0.73) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL9120313 | 0.90 | CYSLTR2 (0.58) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL9499619 | 0.90 | CYSLTR2 (0.58) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES | |
| SCHEMBL4466433 | 0.90 | CYSLTR1 (0.60) | PLA2G4ACYSLTR2CYSLTR1MEN1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007112747-A1 | IMMUNOGEN COMBINATIONS | CURALOGIC A/S (DK) | 2007-10-11 | — | — | WO | claimed |
| US-6333361-B1 | HYDROXYPROPYL CELLULOSE WITH ZAFIRLUKAS | ZENECA LIMITED (GB) | 2001-12-25 | — | — | US | claimed |
| US-6143775-A | PHYSICAL FORM OF ZAFIRLUKAST; ASTHMA | ZENECA LIMITED (GB) | 2000-11-07 | — | — | US | claimed |
| EP-1030664-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ZAFIRLUKAST | AstraZeneca UK Limited (GB) | 2000-08-30 | — | — | EP | claimed |
| US-5993859-A | N-(4-(5-(CYCLOPENTYLOXYCARBONYL)AMINO-1-METHYLINDOL-3-YL-METHY L)-3-METHOXY BENZOYL)-2-METHYL-BENZENESULPHONAMIDE AND POLYVINYLPYRROLIDONE. | ZENECA LIMITED (GB) | 1999-11-30 | — | — | US | claimed |
| WO-1999025338-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ZAFIRLUKAST | ASTRAZENECA UK LIMITED (GB) | 1999-05-27 | — | — | WO | claimed |
| US-5612367-A | Orally administering an amorphous physical form of zafirlukast in combination with polyvinylpyrrolidone | ZENECA LIMITED (GB) | 1997-03-18 | — | — | US | claimed |
| US-5583152-A | Use of N-(4-(5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl)-3 -methoxybenzoyl)-2-methyl-benzenesulphonamide, zafirlukast; allergic asthma, inflammatory diseases, endotoxic conditions or traumatic shock | ZENECA INC. (US) | 1996-12-10 | — | — | US | claimed |
| EP-0490649-B1 | A physical form of N-[4-[5-(cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compositions containing it | ZENECA LTD (GB) | 1996-11-13 | — | — | EP | claimed |
| US-5482963-A | Physical form of N-(4-(5(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl -methyl)3methoxybenzoyl)-2-methylbenzenesulphonamide, zafirlukast; tablet; asthma | ZENECA LIMITED (GB) | 1996-01-09 | — | — | US | claimed |
| EP-0490648-B1 | Pharmaceutical agents | ZENECA LTD (GB) | 1995-12-06 | — | — | EP | claimed |
| US-5319097-A | Physical form of leukotriene antagonist such as zafirlukast, N-(4-(5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl)-3-methoxybenzoyl)-2methylbenzenesulfonamide; spray drying in acetone | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-06-07 | — | — | US | claimed |
| US-5294636-A | Such as zafirlukast; leukotriene antagonist; metered dose inhalers | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-03-15 | — | — | US | claimed |
| EP-0490649-A1 | A physical form of N-[4-[5-(cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compositions containing it | ZENECA LIMITED (GB) | 1992-06-17 | — | — | EP | claimed |
| EP-0490648-A1 | Pharmaceutical agents | ZENECA LIMITED (GB) | 1992-06-17 | — | — | EP | claimed |
| EP-0199543-B1 | HETEROCYCLIC AMIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-12-04 | — | — | EP | claimed |
| US-4859692-A | Heterocyclic amide derivatives and pharmaceutical use | ICI AMERICAS INC. (US) | 1989-08-22 | — | — | US | claimed |
| JP-4266824-A | — | — | None | — | — | JP | disclosed |
| US-4859692-A | Heterocyclic amide derivatives and pharmaceutical use | ICI AMERICAS INC. (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0199543-A2 | Heterocyclic amide derivatives | ICI AMERICAS INC. (US) | 1986-10-29 | — | — | EP | disclosed |